Nevertheless, taken together these results would suggest interdependence and that C-reactive protein, a routinely available and well-standardised clinical laboratory measurement, is a useful surrogate measure of interleukin-6 activity in patients with NSCLC. This evidence concerns the gene IL6 and non-small cell lung carcinoma.